NodThera Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Boston, MA – NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced